Step-by-Step Roadmap for United States Medical Device Registration

1. Key takeaways

The six steps of United States device registration are: step 1, device definition and classification determination; step 2, designation of a US Agent; step 3, establishment registration; step 4, device listing; step 5, the premarket pathway (510(k), De Novo, PMA, or HDE, or confirmation of exemption); and step 6, activation of post-market obligations. Steps 2 through 4 are connected in series: if any one of them is missing, the dossier in step 5 cannot be accepted, and the goods cannot clear customs. The sequence is not procedural decoration; each step consumes the output of the one before it, so compressing or reordering the chain creates rework rather than speed. A project plan built on this roadmap, with a deliverable and an owner attached to every step, converts a complicated multi-agency process into a trackable program that can be audited internally at any point.

• Step 1 determines the product code, and the product code determines exemption status, listing grouping, and the premarket pathway.
• Step 2 must precede step 3, because registration cannot be completed for a foreign establishment without a designated agent.
• Step 3 carries a 30-day initial deadline under 21 CFR 807.22(a), with annual renewal from October 1 through December 31 under 21 CFR 807.22(b)(1)(3).
• Step 5 is not always a submission; where the product code is exempt, the step becomes recording the exemption basis with evidence retained.
• Step 6 should start before the first shipment, with MDR, correction and removal, and UDI processes live ahead of any release.

2. Legal basis

The authorities below anchor each of the six steps. Read top to bottom, the table follows the same order as the roadmap itself, so a project manager can use it directly as the regulatory spine of the milestone plan and attach each row to the corresponding deliverable in the project schedule.

3. Expert insights

Insight one: an error at step 1 forces rework of everything that follows.

The classification determination decides the product code, and the product code decides exemption status, the way listings are grouped, and the premarket pathway. Changing the product code pulls the listing numbers and the dossier structure along with it. GRZAN therefore treats step 1 as a standalone deliverable in every project, never merged into later steps for delivery or for pricing. The discipline sounds bureaucratic until the alternative happens: a submission drafted against the wrong code must be reorganized line by line, and internal documents from the quality manual to the labeling artwork may need revision before the file can even be discussed with the reviewing center. A few disciplined days at the start prevent weeks of redirection later.

Insight two: the deadlines for steps 2, 3, and 4 are statutory, not advisory.

Initial registration is due within 30 days (21 CFR 807.22(a)), the annual renewal runs from October 1 through December 31 (21 CFR 807.22(b)(1)(3)), and changes to information must be reported within 30 days (21 CFR 807.22(b)(2)). Each deadline carries its own distinct consequence of failure, from an inactive establishment status to a border detention under Import Alert 99-34. Because the consequences differ, the calendar controls must differ as well: the annual window needs a start reminder in early October, while the change-update duty needs a standing rule that any address, contact, or activity change triggers the 30-day clock immediately upon occurrence.

Insight three: step 5 does not always happen, but exemption must still be evidenced.

Where the product code falls within the 510(k) exemption scope, step 5 becomes the recording of the exemption basis. Evidence of the exemption must be retained so that it can be shown during an FDA inspection or a customs verification. The record should quote the classification regulation, state the exemption conditions, and confirm that the product as designed meets every one of them. An exemption claim without a file behind it is vulnerable precisely when it matters, because the person asked to defend it may not be the person who made the original determination, and reconstructing the reasoning months later is slow and unreliable.

Insight four: step 6 should start before the 510(k) is even in hand.

The MDR event file, the correction and removal reporting process, and UDI and GUDID data submission should all exist before the first shipment leaves. Otherwise, if an event occurs on that first consignment, the enterprise has no process to follow, and the response becomes improvised at the very moment when regulatory discipline is most visible. Building the post-market processes early also has a quieter benefit: they surface questions about labeling, distribution records, and complaint intake while design changes are still cheap, rather than after the product is in the field.

4. Practical recommendations

• Manage the six steps with a milestone table, setting a deliverable and an accountable owner for every step.
• For step 1, issue a classification determination and product code confirmation statement as a signed document, and use it as the input to all subsequent work.
• Complete steps 2, 3, and 4 before the first United States purchase order is signed, so no commercial commitment outruns the registration chain.
• For step 5, prepare the dossier by pathway, and where the route is 510(k) or De Novo, use the eSTAR template from the beginning.
• For step 6, bring the three processes, MDR, 806 corrections and removals, and UDI, live before the first shipment.

5. Verification checklist

• □ Step 1: the FD&C Act section 201(h) determination and product code confirmation are complete, with written records.
• □ Step 2: the US Agent has been designated and written confirmation of consent obtained.
• □ Step 3: establishment registration is complete and the registration number has been obtained.
• □ Step 4: device listing is complete, with the listing number structure conforming to 21 CFR 807.28(f).
• □ Step 5: the premarket pathway has been determined, or the exemption basis is retained in writing.
• □ Step 6: the three processes for MDR, 806, and UDI are live.
• □ No first shipment to the United States has been scheduled before all six steps are complete.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com